Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H7N9 avian influenza virus-like particle vaccine
- Development stage
- Discontinued
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The H7N9 avian influenza virus-like particle (VLP) vaccine is a plant-derived vaccine candidate developed by Medicago Inc. (a subsidiary of Mitsubishi Tanabe Pharma) for the prevention of H7N9 avian influenza. Produced using the proprietary Proficia platform, the vaccine utilizes *Nicotiana benthamiana* plants as bioreactors to express recombinant hemagglutinin (HA) proteins from the H7N9 virus strain A/Hangzhou/1/2013. These HA proteins self-assemble into non-infectious VLPs that mimic the native structure of the virus but lack genetic material, rendering them unable to replicate. To enhance immunogenicity, the vaccine was frequently formulated with GLA (glucopyranosyl lipid A), a synthetic Toll-like receptor 4 (TLR4) agonist adjuvant. Although the vaccine demonstrated the ability to induce robust antibody responses in clinical trials, the development program was terminated in 2023 following the closure of Medicago's operations by Mitsubishi Tanabe Pharma.
- Other names
- Plant-derived H7N9 VLP vaccineMedicago H7N9 vaccineH7N9 VLP + GLA
02
Targets
SA (Sialic acid)
Beyond the preview
Go deeper on H7N9 avian influenza virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H7N9 avian influenza virus-like particle vaccine.